ODIN grant supports collaborative project “SynPhONY” to accelerate development of phage-based therapies

-

ODIN grant supports collaborative project “SynPhONY” to accelerate development of phage-based therapies

Antimicrobial resistance (AMR) is a global health challenge and is expected to cause more than 10 million deaths by 2050. Chronic wounds and urinary tract infections (UTIs) are particularly difficult to treat because antibiotic-resistant bacteria can protect themselves in ways that make today’s treatments non effective. This leaves patients with limited therapeutic options and highlights the unmet need for new, targeted solutions.
To address this challenge, an ODIN-funded collaborative project, led by Professor Hanne Ingmer from the University of Copenhagen’s Department of Veterinary and Animal Sciences, will bring together academic researchers and industry partners to develop next-generation tools for advancing phage-based therapies. Assistant Professor Ifigeneia Kyrkou and Assistant Professor Esther Lehmann played a key role in forming the consortium by pitching the project at ODIN events and connecting with the partners involved.
Phage therapy uses naturally occurring viruses that selectively kill harmful bacteria and offers a promising alternative when antibiotics fail. However, therapeutic success remains limited because we cannot yet predict how phages will behave inside the human body during real infection conditions. Existing animal models simply do not accurately mimic the complexity of human tissues or the way bacteria act during an infection, making it difficult to identify which phages will be most effective in patients.
To close this gap, Associate Professor Mariaceleste Aragona and her team from the Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW, will develop scalable human skin and bladder infection models. These models will allow to test whether selected phages can safely and effectively eliminate harmful bacteria in wound and urinary infections. Industry and clinical partners will support this work by for example providing real-world bacterial samples from used wound dressings, catheters and urine.
In our effort to identify the next generation of therapeutic phages, phage libraries of our partners will be tested for their effectivity in the wound and urinary tract infection models, and new phages from hospital wastewater and patient materials will be isolated. Because phages exist in many variants, this project will also use pre-trained AI tools to aid future predictions of the most promising phages and build a clinically relevant phage library. By combining information from phenotypic assays, AI-guided phage selection, humanized UTI and wound infection models and real-world bacterial samples, the consortium aims to create a scalable screening that partners can use to accelerate the discovery of the next-generation phage-based treatments.
This outcome will be a fundamental tool for identifying effective phages faster and more reliably, helping pave the way for future treatments against AMR-related infections. In the long term, this work has the potential to curb antibiotic resistance, shorten treatment time and reduce the burden of long hospital stays.
The collaboration partners include:The University of Copenhagen, Aarhus University, Novo Nordisk Foundation Center for Stem Cell Medicine, (reNEW), Hospital Amager & Hvidovre, Coloplast A/S, Invitris, Inicure AB, LABOKLIN GmbH & Co, and Phagos.
Article taken from, copyright belongs to : https://renew.science/stories/odin-grant-supports-collaborative-project-synphony-to-accelerate-development-of-phage-based-therapies/

Comments

Post a Comment

Most Consulted Articles

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

-
Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more